Allogeneic Cultured Keratinocytes in the Treatment of Leg Ulcers

A Pilot Study

MARCUSSON JAN A, LINDGREN CARIN, BERGHARD ANNA and TOFTGÅRD RUNE

1Center for BioTechnology, Karolinska Institute, NOVUM and 2Department of Dermatology, Huddinge Hospital, Huddinge, Sweden

Forty-two patients (10 males and 32 females) with 52 chronic leg ulcers were treated with sheets of cultured allogeneic keratinocytes. Sixty-five percent of the ulcers healed completely and the healing rate differed between various diagnostic groups. The best results were obtained in patients with venous ulcers and wounds with mixed etiology, whereas less improvement was observed with ischaemic ulcers. Rheumatic ulcers also responded well in combination with oral corticosteroids. The overall impression was that the grafting procedure markedly enhanced wound healing. Key words: Allograft; Wound healing.

(Accepted July 25, 1991.)


J. A. Marcusson, Department of Dermatology, Huddinge Hospital, S-141 86 Huddinge, Sweden.

Recent Swedish studies have shown that the prevalence of leg and foot ulcers in the Gothenburg area was between 0.2 and 0.4% (1-3). Similar figures have been obtained in another investigation (4). The frequency of ulcer occurrence increases with patient age and it has been shown that the number of ulcers with arterial etiology has increased over the last 10 year period (2, 3). The cost of care of ulcer patients is high and will increase as the elderly population increases (5), thus new methods with the potential to improve the healing process are greatly needed. Topically applied autologous and allogeneic cultured keratinocytes have been used for healing wounds such as burns, leg ulcers and wounds after surgical excision of skin (6). Autologous cultured keratinocytes seem to act like a transplant and the graft has been shown to “take” (6). In situ hybridisation studies using a Y-chromosome specific probe and patients and donors of opposite sex have demonstrated that this is not the case with allogeneic grafts (7, 8). Cultured allogeneic keratinocyte sheets have been reported to enhance healing of leg ulcers (9-13). We have evaluated this method on unslected patients with leg ulcers of varying etiology.

MATERIALS AND METHODS

The patient material consisted of 42 subjects (10 males and 32 females). The median age was 71 years (range 46-89). All subjects were out-patients at the leg ulcer clinic of the Dermato Venereology Clinic at Huddinge Hospital and belonged to various diagnostic groups. The ulcers were situated on the lower legs and feet and the patients were categorized as follows (for details see Table 1):

Venous ulcers
Ulcers situated at the medial distal third of the legs: ankle pressure (AP) > 100 mmHg, ankle index (AI): systolic blood pressure of the ankle/systolic blood pressure of the arm > 0.9.

Ischaemic ulcers
AP mostly < 100 mmHg and AI < 0.9.

Combined ulcers
Showing features of a venous ulcer but AP < 100 mmHg and AI < 0.9.

Foot ulcers
Ulcers situated on the feet below the shoe line and malleoli.

Mixed etiology ulcers
Wounds which did not fit into the above categories and which had an apparent traumatic or postinfectious cause. One patient had necrobiosis lipoidica and two ulcers in a transplanted area.

Rheumatic wounds
Long-standing wounds and concomitant rheumatic arthritis. AP > 100 mmHg and AI > 0.9.

Keratinocyte culture
The skin donors were neonatal and the mothers had been tested for HIV and Hepatitis B. Keratinocytes were prepared from human foreskin by enzymatically dissociating epidermis from dermis with 0.5% Pronase (Boehringer), at 37°C for 20-40 min. Cells were seeded on lethally irradiated Swiss 3T3 mouse fibroblasts as described by Green et al. (14) and grown in 5% CO2 at 37°C. The medium consisted of Dulbecco's modified Eagle medium (DMEM); Hams F12 (3:1; Gibco or Nord Você) supplemented with 5% fetal calf serum (Gibco), 5 μg/ml insulin (Sigma), 0.4 μg/ml hydrocortisone (Sigma), 10 ng/ml epidermal growth factor (Sigma), 10⁻¹⁰ M chola toxin (Sigma), and 1.8 x 10⁻⁴ M adonine (Sigma). The medium for primary cultures also contained penicillin/streptomycin (100 IU/100 μg x ml⁻¹; NordVocê) and Fungizone (0.25 μg x ml⁻¹; Gibco). The keratinocytes were split 1:4 before reaching confluence and no feeder cells were used in the second or third passages. Before the keratinocyte sheets were used for grafting, cholera toxin was excluded from the media.

The keratinocyte sheets used for grafting consisted of 1 basal and 1-2 suprabasal cell layers and were prepared from cells in the second or third passage. The cells were detached from the plastic in intact sheets by using Dispase II (0.4%, 5 min, room temperature; Boehringer), rinsed in sterile phosphate buffered saline and “backed” on vaseline gauge.

Patient care and grafting procedure
The wounds were prepared for grafting in the following way: for debriement, a CO₂ laser was mostly used with superficial vaporisation (1-4 W, continuous ray); sometimes curettage was done after wound occlusion with hydrocolloid dressings. No grafting was performed until at least one week after these procedures. Cellulitis was treated with appropriate antibiotics. In the case of leg swelling and thick wound edges, mechanical therapy with sequential pneumatic compression was given (or 30-90 min (Turbo Puls System AB, Uppsala, Sweden). During the treatment the wounds were covered with gauze soaked in chlorhexidine solution (0.25%). The usual pressure was 70-80 mmHg. Both the pressure and time was adjusted to avoid pain in the case of ischaemia. Prior to grafting, the area of the wound was traced using transparent film and then measured using Image 1.22 (public domain developed by W. Rasband, NIH, research services Branch), and a Mac II with a flatbed scanner (Microtek).
Table I. The patient's material and results. The values shown are median values and the ranges are given within parenthesis

<table>
<thead>
<tr>
<th></th>
<th>No of wounds</th>
<th>Ankle pressure (mmHg)</th>
<th>Ankle index</th>
<th>Wound duration before grafting (weeks)</th>
<th>Wound area (cm²)</th>
<th>Healing time (weeks)</th>
<th>Number of keratinocyte graftings</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>(healed/non healed)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Venous ulcers (M=2, F=11; Age: 70 (49–89))</td>
<td>17/34</td>
<td>175</td>
<td>1.20</td>
<td>50 (15-156)</td>
<td>5.4 (0.7-34.1)</td>
<td>9 (5-26)</td>
<td>5 (1-10)</td>
</tr>
<tr>
<td>Ischaemic ulcers (M=1, F=5; Age: 81 (80–86))</td>
<td>7/16</td>
<td>100</td>
<td>0.65</td>
<td>156 (26-156)</td>
<td>12.6 (3.5-55.1)</td>
<td>32 (6-32)</td>
<td>6 (1-15)</td>
</tr>
<tr>
<td>Combined ulcers (M=1, F=1; Age: 64 (62-74))</td>
<td>2/20</td>
<td>75</td>
<td>0.6</td>
<td>34 (16-54)</td>
<td>8.1 (0.7-15.5)</td>
<td>21 (3-40)</td>
<td>3 (1-5)</td>
</tr>
<tr>
<td>Foot ulcers (F=5; Age: 82 (63-85))</td>
<td>8/35</td>
<td>210</td>
<td>1.40</td>
<td>16 (12-26)</td>
<td>8.8 (6-17.1)</td>
<td>7 (6-8)</td>
<td>3 (2-5)</td>
</tr>
<tr>
<td>Mixed etiology (M=3, F=7; Age: 73 (43-80))</td>
<td>10/82</td>
<td>160</td>
<td>1</td>
<td>23 (12-156)</td>
<td>9.3 (1.1-188)</td>
<td>5 (3-28)</td>
<td>3 (1-11)</td>
</tr>
<tr>
<td>Rheumatic wounds (M=3, F=5; Age: 64 (48-83))</td>
<td>8/71</td>
<td>165</td>
<td>1.07</td>
<td>20 (10-156)</td>
<td>8.5 (2.1-112)</td>
<td>24 (4-40)</td>
<td>7 (1-10)</td>
</tr>
</tbody>
</table>

M and F indicate number of male and female patients

The sheets of keratinocytes were applied directly on the wound bed with the basal cells down. The sheets were overlaid with gauze pads to establish close contact between the graft and the wound bed. A firm elastic bandage was applied to keep the graft in place. Patients were asked to remain in bed for 3–4 days and then the wound was inspected. If there was no secondary infection or eczema of the surrounding skin, the ulcer was soaked in saline without removal of the graft. The dressing was changed every second day. If complications occurred the dressing was changed daily. When the ulcers were covered with new epithelium they were defined as healed. The study was performed during September 1989 to May 1990.

RESULTS

Thirty-four out of 52 ulcers (65%) were completely healed (Table I and Fig. 1). The healing rate differed within the various categories. The most promising results were obtained in the venous ulcer group which showed 50% healing within 3 months compared with 40% healing of all wounds (Fig. 1).

Venous ulcers

Thirteen of 17 ulcers healed completely in 13 patients and the median healing time was 9 weeks. The median wound area of the healed ulcers was 3.1 cm² (range 0.7–5.8) and of the non-healed ulcers 12.3 cm² (range 2.8–34.1). Among the four wounds that did not heal, 2 increased their areas by 32% and 110%, respectively; one decreased by 50% and one ulcer remained unchanged. The reason for the incomplete healing could be due to concomitant diseases such as secondary atrophy blanche, swelling of the lower legs due to heart incompensation and swelling due to lymphoedema. The larger standing wound area in the latter case could also negatively influence the results.

Ischaemic ulcers

Out of 7 ulcers 1 healed after 32 weeks; 10 graftings were performed. Among the other 6, three increased in size (7–55%) and 3 decreased (34–60%). The AP and AI in the healed subject was 90 mmHg and 0.8 respectively; the median AP and AI in the non-healing group was 110 mmHg (90–150) and 0.65 (0.54–0.8). The initial areas of the ulcers were 3.8 cm² in the healed group and 16 cm² (3.5–55) in the non-healed group.

---

*Acta Derm Venereol (Stockh) 72*
Combined ulcers

All ulcers in this group healed completely (Table I).

Foot ulcers

Three out of 8 wounds healed. The median wound area in the healed group was 1.9 cm² (0.9–5.8) and in the non-healed group 11.9 cm² (4.2–17.1). Two of the patients in the non-healing group had wounds which were of the secondary atrophy blanche type.

Mixed etiology ulcers

Eight out of 10 ulcers in this group healed after treatment and in the remaining 2 there was a reduction of the wound area by 60%. One patient that healed had an AI of 0.67 but the AP was 120 mmHg.

Rheumatic wounds

Seven out of 8 wounds in this group healed completely; one increased in size by 60%. Concomitant therapy was given with prednisolone (15–25 mg/day) or cyclophosphamide (100 mg/day). Of two patients treated with plasmapheresis, one healed completely and the other patient’s ulcer increased in size.

Case report

A 77-year-old female with a longstanding (20 months) ulcer with mixed etiology (AI 1.0; AP 170 mmHg) had been given conventional treatment with no promoting effect on healing. Pinch grafting initially gave a reduction of ulcer area from 35 cm² to 10 cm². During the following 15 weeks, the healing process stopped but restarted when keratinocyte grafts were applied (Fig. 2).

DISCUSSION

Our results indicate that the keratinocyte grafts were most effective in stimulating healing of venous ulcers (13 to 17), ulcers with mixed etiology (8 to 10) and rheumatic ulcers (7 of 8). Less improvement was demonstrated for ischaemic ulcers. Large ulcers seemed to respond less well compared to smaller ones but in most cases a significant reduction in size was observed. The data indicate a marked positive effect which is in agreement with previous studies (9–13). An interesting observation is the complete healing in the combined ulcer group, despite the low AP and AI (Table I). This indicates that it is not possible to exclude those patients from treatment with cultured allograft since the end results are not obvious until

*Acta Derm Venereol (Stockh)* 72
the grafting procedure has been tried. A combined treatment was used in the venous and rheumatic ulcer groups. Thus patients with venous ulcers received active compression therapy which might have contributed to the healing. Adjunctive therapy was also given to patients with rheumatic ulcers; in addition to keratinocyte grafting they have been treated with either prednisolone, cyclophosphamide or plasmapheresis.

The data clearly show that the selection of patients is important since the result vary between the different diagnostic groups. This puts into focus the need to evaluate the beneficial clinical effect of keratinocyte grafting compared to other treatments in a controlled study with well defined clinical patient groups.

The clinical impression is that grafting with allogeneic cultured keratinocytes accelerates the healing process. We confirm the previously reported observations concerning "edge" and "central" wound effects (10–12). The "edge" effect (Fig. 2C) was obvious and manifested itself as a translucent blue/red edge at the periphery of the wound consisting of epithelium growing towards the wound center. The "central" effect (Fig. 2A) presented itself as islands of epithelium in the central part of the ulcer from which the epithelium grew out radially. The latter phenomenon is believed to represent keratinocyte outgrowth from the hair follicles.

No obvious clinical "take" and no signs of graft rejection have been registered. However, we cannot exclude that an immunological reaction has occurred and contributed to the effect of the graft, for example through the release of cytokines. A recent study (16) using an in vitro dermal explant model for studying stimulatory effects of mitogens and cultured allogeneic keratinocyte sheets on re-epithelisation showed that the stimulatory effect of the cultured cells was greater than that of the mitogens. Since the cultured keratinocyte allografts do not remain permanently on the wound it must be assumed that they in some way stimulate the proliferation and/or migration of the host keratinocytes. This stimulation could be due to factors secreted by the cultured keratinocytes, cell-cell or cell-matrix interactions.

ACKNOWLEDGEMENTS
This study was supported by grants from the Welander foundation and from the Swedish National Board for Technical Development (STUF) (project number 88-0322P). The authors are grateful to Dr. J. M. Leigh, London Hospital, Great Britain, for introduction to the field of keratinocyte grafting and to Barbro Andersén for excellent technical assistance.

REFERENCES